The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, circulating, ctDNA, DNA, liquid, review, test, tumor | 2 Comments »
A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, genetic, inconsistency, liquid, medicine, personalized, problem, result, test | 2 Comments »
A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, cell, circulating, CTC, liquid, selection, Treatment, tumor | Leave a comment »
A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, cell, circulating, CTC, expression, liquid, PTEN, tumor | 2 Comments »
A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of progressive forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, biopsy, expression, liquid, plasma, receptor | Leave a comment »
Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, CancerIntercept, genomics, liquid, pathway | Leave a comment »
The “New” Prostate Cancer InfoLink wishes to very clearly warn its readers about the near to complete lack of any meaningful data — as yet — supporting the use of a new form of test called a “liquid biopsy” in the diagnosis and monitoring of a range of different types of high-risk cancer (clinically significant, high-risk prostate cancer included). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracay, biopsy, liquid, value | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 